Abstract: Epidermal growth factor receptor (EGFR) inhibitors are currently widely used for targeted lung cancer therapy. Targeted therapy evaluation principally relies on genetic testing or rough clinical estimation. PET receptor imaging is highly sensitive and specific. According to domestic and foreign literature, PET imaging using radiolabeled EGFR-targeting agents can be used to predict and monitor therapy response. This paper presents new evaluating methods for targeted lung cancer therapy.